ZVRA Q4 2024 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-8.9% YoY

Gross Profit

$11M88.7% margin

Operating Income

-$15M-128.0% margin

Net Income

-$36M-296.8% margin

EPS (Diluted)

$-0.67

QoQ Revenue Growth

+225.9%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$178M

Total Liabilities

$138M

Stockholders' Equity

$40M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$13M	-8.9%
Gross Profit	$11M	$10M	+2.4%
Operating Income	-$15M	-$15M	-5.1%
Net Income	-$36M	-$15M	-135.9%